title: Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items.
abstract: Rivastigmine has been shown to improve cognition in patients with Parkinson's disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for ADAS-cog item scores and for 3 cognitive domain scores. A total of 362 patients were randomized to 3 to 12 mg/d rivastigmine capsules and 179 to placebo. Patients with PDD receiving rivastigmine improved versus placebo on items: word recall, following commands, ideational praxis, remembering test instructions, and comprehension of spoken language (P < .05), with standardized mean differences ranging from 0.04 to 0.30. Rivastigmine also showed significant effects versus placebo on all domains: memory, language, and praxis. The ADAS-cog is sensitive to broad cognitive changes in PDD. Overall, rivastigmine was associated with improvements on individual cognitive items and general cognitive domains.
authors.affiliation: Department of Neurology, Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536, USA. fascom@email.uky.edu
authors.forename: Frederick A
authors.initials: FA
authors.lastname: Schmitt
authors.forename: Dag
authors.initials: D
authors.lastname: Aarsland
authors.forename: Kolbjørn S
authors.initials: KS
authors.lastname: Brønnick
authors.forename: Xiangyi
authors.initials: X
authors.lastname: Meng
authors.forename: Sibel
authors.initials: S
authors.lastname: Tekin
authors.forename: Jason T
authors.initials: JT
authors.lastname: Olin
mesh_terms: D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy; D003704:Dementia / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*; D048448:Phenylcarbamates / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D000068836:Rivastigmine; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine
references.citation: Neurology. 2005 Oct 25;65(8):1239-45
references.pmid: 16247051
references.citation: Neurology. 2005 Dec 27;65(12):1907-13
references.pmid: 16282276
references.citation: J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):324-5
references.pmid: 8795611
references.citation: Neuropsychology. 2000 Apr;14(2):233-46
references.pmid: 10791863
references.citation: Int J Geriatr Psychiatry. 2001 Jul;16(7):653-66
references.pmid: 11466744
references.citation: Neuropsychology. 2002 Oct;16(4):577-90
references.pmid: 12382995
references.citation: Neurology. 2007 Jan 30;68(5):326-37
references.pmid: 17261678
references.citation: Am J Alzheimers Dis Other Demen. 2010 Mar;25(2):142-8
references.pmid: 19359706
references.citation: Arch Neurol. 2003 Mar;60(3):387-92
references.pmid: 12633150
references.citation: Lancet Neurol. 2004 Oct;3(10):622-6
references.pmid: 15380159
references.citation: Neurology. 2005 Nov 22;65(10):1654-6
references.pmid: 16301500
references.citation: Int J Clin Pract. 2009 May;63(5):799-805
references.pmid: 19392927
references.citation: J Neurol Neurosurg Psychiatry. 1985 May;48(5):413-21
references.pmid: 3998751
references.citation: N Engl J Med. 2004 Dec 9;351(24):2509-18
references.pmid: 15590953
references.citation: J Clin Exp Neuropsychol. 2001 Oct;23(5):592-8
references.pmid: 11778636
references.citation: Neuropsychology. 2005 Jan;19(1):106-14
references.pmid: 15656768
references.citation: J Comp Neurol. 2003 Aug 11;463(1):25-43
references.pmid: 12811800
references.citation: J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76
references.pmid: 18344392
references.citation: Brain. 1992 Dec;115 ( Pt 6):1727-51
references.pmid: 1486458
references.citation: Curr Alzheimer Res. 2007 Jul;4(3):277-93
references.pmid: 17627485
references.citation: Mov Disord. 2006 Nov;21(11):1899-907
references.pmid: 16960863
references.citation: Int J Geriatr Psychiatry. 2007 May;22(5):456-67
references.pmid: 17380489
references.citation: J Neurol Neurosurg Psychiatry. 2007 Oct;78(10):1064-8
references.pmid: 17287236